Should revascularisation be recommended for atherosclerotic renal artery stenosis?

V Jha
Additional Professor of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

**TITLE** Revascularization versus medical therapy for renal-artery stenosis

**AUTHORS** ASTRAL Investigators


**DECLARATION OF INTERESTS** Professor Jha has declared no conflict of interests.

**SUMMARY**

This multicentric, multinational, randomised controlled trial (RCT) was aimed to see if percutaneous revascularisation of the renal arteries in atherosclerotic renovascular disease provided clinical benefits. A total of 806 patients in whom the benefits of revascularisation were thought to be uncertain by their treating physicians were randomised to the medical therapy or the revascularisation plus medical therapy arms. Randomisation was stratified according to serum creatinine levels, Cockcroft-Gault glomerular filtration rate (GFR), severity of renal-artery stenosis, kidney length and rate of progression of renal impairment before entry. The primary outcome was the rate of change of renal function as measured by the reciprocal of the serum creatinine. Blood pressure, time to renal and major cardiovascular events and mortality were additional outcome variables.

Of the 403 patients randomised to the revascularisation arm, 335 underwent the procedure; 95% had a stent placed. The technical success was 95%. The crossover rate to revascularisation in the medical therapy group was 6%. Patients were followed up for a median period of 34 months. The rate of change of the slope of the inverse of serum creatinine during follow-up was not different in the two groups (–0.07×10⁻³ and –0.13×10⁻³ l/mol/year in the revascularisation and medical therapy groups respectively). There was a difference favouring revascularisation of 0.06×10⁻³ l/mol/year (95% confidence interval, –0.002–0.13; p=0.06). There was no difference in the change in serum creatinine, systolic blood pressure or rates of renal events, major cardiovascular events and death. The medical therapy group required more antihypertensive agents at one year (2.97 vs 2.77, p=0.03). There were no differences in the outcome in any of the predefined subgroups, including those with high-grade or bilateral stenosis or impaired or decreasing kidney function at entry. Thirty-one patients developed complications within 24 hours of the procedure, and another 55 patients in the next 30 days. These were deemed to be serious in 23 patients, including two deaths and three amputations. The authors concluded that there was no evidence of a worthwhile clinical benefit from revascularisation in patients with atherosclerotic renovascular disease.

**OPINION**

Atherosclerotic renal artery stenosis (RAS) is the most common correctable cause of hypertension. When bilateral or present in a solitary functioning kidney, RAS can cause a progressive loss of renal function. Ischaemic nephropathy is listed as the cause of end-stage renal disease in about 12–20% of patients. Atherosclerotic RAS increases the risk for cardiac events (pulmonary oedema, refractory heart failure or acute coronary ischaemia), stroke and peripheral vascular disease. Renal insufficiency in patients with RAS is associated with markedly decreased survival. In a study of patients undergoing coronary angiography, RAS was a stronger independent predictor of all-cause mortality than congestive heart failure, left ventricular ejection fraction or the level of renal dysfunction.

The benefits of revascularisation in RAS may seem self-evident. ‘Drive-by’ angiographies are frequently performed during coronary or peripheral angiograms. Incidental RAS is discovered in 15–35%, and prompts percutaneous renal angioplasty and stenting in many. The American Heart Association guidelines on this procedure have been criticised, not least because revascularisation is associated with complications in a significant proportion of patients.

Whether revascularisation provides tangible clinical benefits remains unclear. Percutaneous renal angioplasty alone is technically unsatisfactory for the ostial lesions of atherosclerotic RAS, and has high restenosis rates. Percutaneous renal angioplasty trials have failed to show an effect on blood pressure or kidney function. A pooled meta-analysis suggested a modest improvement in blood pressure with revascularisation. These studies, however, were bedevilled by methodological issues, including inadequate sample size and imprecise patient selection criteria. A significant proportion crossed over from medical therapy to angioplasty, reducing the validity of the results.

Following the introduction of stents, the technical success of revascularisation improved and the risk of restenosis came down. Observational data and non-randomised
On this background, the Angioplasty and STenting for Renal Artery Lesions (ASTRAL) study results are significant. This was a well-conducted RCT with predefined outcomes. Unlike previous trials, not many patients crossed over from the conservative to the intervention arm. However, ASTRAL turned out to be another addition to the list of negative studies in the nephrology field.

Do the results sound a death knell for revascularisation for atherosclerotic RAS? Perhaps not, since concerns remain that make this study less than definitive. The inclusion criteria are vague, to say the least. Patients were required to have ‘stenosis in at least one renal artery that was considered potentially suitable for endovascular revascularisation’ and ‘if the patient’s doctor was uncertain that the patient would definitely have a worthwhile clinical benefit from revascularisation’. This unnecessarily excluded patients who in the doctors’ opinion would benefit from the procedure and says little about the characteristics of the studied patients.

A closer inspection of the data reveals the crucial fact that 321 out of the 403 (80%) patients in the revascularisation group did not have stenosis that would be considered clinically significant according to current knowledge. This means that the likelihood of benefit in them was low in any case. In fact, only 163 patients in both groups had high-grade (≥70%) RAS involving both renal arteries or the artery supplying a single functioning kidney. Considering grade (≥70%) RAS involving both renal arteries or the artery supplying a single functioning kidney. Considering grade (≥70%) RAS involving both renal arteries or the artery supplying a single functioning kidney. Considering grade (≥70%) RAS involving both renal arteries or the artery supplying a single functioning kidney. Considering grade (≥70%) RAS involving both renal arteries or the artery supplying a single functioning kidney. Considering grade (≥70%) RAS involving both renal arteries or the artery supplying a single functioning kidney.

In summary, the result of the ASTRAL trial can be interpreted to mean that the best treatment of RAS remains uncertain unless we find a good means of identifying patients suitable for the procedure, preferably in a non-invasive way. Brain natriuretic peptide could be one such marker. Future trial protocols need to include these.

REFERENCES

5 Dear JW, Padfield PL, Webb DJ. New guidelines for drive-by renal angiography may lead to an unjustifiable increase in percutaneous intervention. Heart 2007; 93:1528–32. doi:10.1136/hrt.2007.117275